References
- Bousquet J, Mantzouranis E, Cruz AA. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126(5):926–938.
- Mallol J, Solé D, Baeza-Bacab M, Aguirre-Camposano V, Soto-Quiros M, Baena-Cagnani C; Latin American ISAAC Group. Regional variation in asthma symptom prevalence in Latin American children. J Asthma 2010; 47(6):644–650.
- Fritscher L, Chapman KR. Omalizumab for asthma: pharmacology and clinical profile. Expert Rev Respir Med 2009; 3(2):119–127.
- Wenzel S. Mechanisms of severe asthma. Clin Exp Allergy 2003; 33(12):1622–1628.
- Wenzel S. Severe asthma: epidemiology, pathophysiology and treatment. Mt Sinai J Med 2003; 70(3):185–190.
- Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172(2):149–160.
- Solèr M. Omalizumab a monoclonal antibody against IgE for the treatment of allergic diseases. Int J Clin Pract 2001; 55(7):480–483.
- European Medicines Agency (EMA). Omalizumab (Xolair®) full prescribing information (EU), 2010. Available at: http://www.ema.europa.eu. Accessed June 15, 2010.
- U.S. Food and Drug Administration. Omalizumab (Xolair®) prescribing information. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103291.htm. Accessed March 5, 2010.
- National Institutes of Health, National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health, 2002. Publication 02–3659.
- Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimized dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19(6):491–498.
- Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47(2):76–83.
- Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res 1996; 5:35–46.
- Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010; 104(10):1410–1416.
- Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F, Fowler-Taylor A, Liu J, Gupta N. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003; 111:278–284.
- Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184–190.
- Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–261.
- Buhl R. Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review. Respir Med 2003; 97:123–129.
- Buhl R, Solèr M, Bensch G, Wolfe J, Everhard F, Champain K, Fox H, Thirlwell J. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20:1088–1094.
- Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–316.
- Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47:81–87.